Could a new injection help people with New-Onset type 1 diabetes keep making insulin?
NCT ID NCT07142252
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a drug called rezpegaldesleukin in people recently diagnosed with type 1 diabetes (within 100 days). The goal is to see if it can help the body keep producing some insulin, reducing the need for injected insulin. 66 participants will receive either the drug or a placebo every two weeks for 26 weeks, and their insulin production will be measured after 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rezpegaldesleukin (NKTR-358)
What this could lead to
If it works, this could help people with new-onset type 1 diabetes keep making some of their own insulin, reducing the need for injected insulin.
What could go wrong
This is an early Phase 2 trial with only 66 people, so results may not apply to everyone. The drug may not preserve insulin production better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Davis Center for Diabetes
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Benaroya Research Institute
RECRUITINGSeattle, Washington, 98101, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Joslin Diabetes Center
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of British Columbia
NOT_YET_RECRUITINGVancouver, British Columbia, V5Z4H4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Florida
RECRUITINGGainesville, Florida, 32610, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84113, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt University
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact